The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
Phones:
+7 (495) 482-4118
+7 (495) 482-4329
  • Toll-free number for subscriptions:
    +8 800 250-18-12
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Kurysheva N.I.

Russian State Research Center − Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency

Neuroprotective properties of latanoprost

Authors:

Kurysheva N.I.

More about the authors

Journal: Russian Annals of Ophthalmology. 2022;138(4): 126‑134

DOI: 10.17116/oftalma2022138041126

Read: 2972 times

Contact the author
Table of contents

NEUROPROTECTIVE PROPERTIES OF LATANOPROST
NEUROPROTECTIVE PROPERTIES OF LATANOPROST

To cite this article:

Kurysheva NI. Neuroprotective properties of latanoprost. Russian Annals of Ophthalmology. 2022;138(4):126‑134. (In Russ.)
https://doi.org/10.17116/oftalma2022138041126

Подписка 2026 Вестник офтальмологии (Russian Annals of Ophthalmology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
The possibilities of antioxidant neuroretinoprotection in the treatment of primary open-angle glaucoma. Russian Annals of Ophthalmology. 2025;(4):49-59
Electrophysiological methods in the diagnosis and moni­toring of glaucoma. Russian Annals of Ophthalmology. 2025;(4):102-109
The effect of initial conservative hypo­tensive therapy on the outcomes of sele­ctive laser trabeculoplasty in primary open-angle glaucoma. Russian Annals of Ophthalmology. 2025;(5):16-22
Modern devi­ces for microinvasive glaucoma surgery. Russian Annals of Ophthalmology. 2025;(5):101-108
Neuroprotective therapy in adva­nced primary open-angle glaucoma. Russian Annals of Ophthalmology. 2025;(6):75-80
Remo­delling of the lamina cribrosa of the sclera in optic nerve axonal injury. Russian Annals of Ophthalmology. 2026;(1):60-69
Trends in glaucoma morbidity in Uzbe­kistan. Russian Annals of Ophthalmology. 2026;(1):108-111
Targets of rational neuroprotection in the therapy of chro­nic cere­bral ischemia and the possibilities of achieving them. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8):96-101
Improving the quality of life and the possibility of pathogenetic therapy in adult patients with cere­bral palsy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(10):75-84
Multimodal antioxidant therapy in ischemic stroke: from MIR trial to bedside. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(12-2):64-71
Abstract:

Glaucoma is the main cause of irreversible blindness in the world. Latanoprost — an ester prodrug of prostaglandin F2α (PGF2α) — was the first prostaglandin analogue used to treat glaucoma. The review shows that latanoprost possesses direct neuroprotective properties such as blocking the entry of calcium ions into neurons and inhibiting the action of caspase-3, inhibiting the activity of cyclooxygenase and activation of polypeptide 2B1 (OATP2B1) and Klotho protein. It is emphasized that when the drug is instilled into the eye, the concentration of the drug inside the vitreous body is twice as high as what is required to ensure the survival of retinal ganglion cells.

Keywords:

glaucoma
prostaglandin analogues
latanoprost
neuroprotection
Xalatan
Xalacom

Authors:

Kurysheva N.I.

Russian State Research Center − Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency

Received:

11.06.2022

Accepted:

21.06.2022

Close metadata

References:

  1. Kurysheva NI. Neuroprotection and neuroregeneration: prospects in the treatment of glaucoma: monograph. M. 2013:88. (In Russ.).
  2. Sharif NA, Kelly CR, Crider JY, Williams GW, Xu SX. Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. J Ocul Pharmacol Ther. 2003;19(6):501-515.  https://doi.org/10.1089/108076803322660422
  3. Ota T, Aihara M, Narumiya S, Araie M. The effects of prostaglandin analogues on IOP in prostanoid FP-receptor-deficient mice. Invest Ophthalmol Vis Sci. 2005;46(11):4159-4163. https://doi.org/10.1167/iovs.05-0494
  4. Cazevieille C, Muller A, Meynier F, Dutrait N, Bonne C. Protection by prostaglandins from glutamate toxicity in cortical neurons. Neurochem Int. 1994; 24(4):395-398.  https://doi.org/10.1016/0197-0186(94)90118-x
  5. Yamagishi R, Aihara M, Araie M. Neuroprotective effects of prostaglandin analogues on retinal ganglion cell death independent of intraocular pressure reduction. Exp Eye Res. 2011;93(3):265-270.  https://doi.org/10.1016/j.exer.2011.06.022
  6. Cantor LB, Hoop J, Wudunn D, Yung CW, Catoira Y, Valluri S, Cortes A, Acheampong A, Woodward DF, Wheeler LA. Levels of bimatoprost acid in the aqueous humour after bimatoprost treatment of patients with cataract. Br J Ophthalmol. 2007;91(5):629-632.  https://doi.org/10.1136/bjo.2006.110155
  7. Jiang J, Ganesh T, Du Y, Thepchatri P, Rojas A, Lewis I, Kurtkaya S, Li L, Qui M, Serrano G, Shaw R, Sun A, Dingledine R. Neuroprotection by selective allosteric potentiators of the EP2 prostaglandin receptor. Proc Natl Acad Sci USA. 2010;107(5):2307-2312. https://doi.org/10.1073/pnas.0909310107
  8. McCullough L, Wu L, Haughey N, Liang X, Hand T, Wang Q, Breyer RM, Andreasson K. Neuroprotective function of the PGE2 EP2 receptor in cerebral ischemia. J Neurosci. 2004;24(1):257-268.  https://doi.org/10.1523/JNEUROSCI.4485-03.2004
  9. Echeverria V, Clerman A, Doré S. Stimulation of PGE receptors EP2 and EP4 protects cultured neurons against oxidative stress and cell death following beta-amyloid exposure. Eur J Neurosci. 2005;22(9):2199-2206. https://doi.org/10.1111/j.1460-9568.2005.04427.x
  10. Liu D, Wu L, Breyer R, Mattson MP, Andreasson K. Neuroprotection by the PGE2 EP2 receptor in permanent focal cerebral ischemia. Ann Neurol. 2005;57(5):758-761.  https://doi.org/10.1002/ana.20461
  11. Ahmad AS, Zhuang H, Echeverria V, Doré S. Stimulation of prostaglandin EP2 receptors prevents NMDA-induced excitotoxicity. J Neurotrauma. 2006; 23(12):1895-1903. https://doi.org/10.1089/neu.2006.23.1895
  12. Hutchinson AJ, Chou CL, Israel DD, Xu W, Regan JW. Activation of EP2 prostanoid receptors in human glial cell lines stimulates the secretion of BDNF. Neurochem Int. 2009;54(7):439-446.  https://doi.org/10.1016/j.neuint.2009.01.018
  13. Zhou P, Qian L, Chou T, Iadecola C. Neuroprotection by PGE2 receptor EP1 inhibition involves the PTEN/AKT pathway. Neurobiol Dis. 2008;29(3): 543-551.  https://doi.org/10.1016/j.nbd.2007.11.010
  14. Abe T, Kunz A, Shimamura M, Zhou P, Anrather J, Iadecola C. The neuroprotective effect of prostaglandin E2 EP1 receptor inhibition has a wide therapeutic window, is sustained in time and is not sexually dimorphic. J Cereb Blood Flow Metab. 2009;29(1):66-72.  https://doi.org/10.1038/jcbfm.2008.88
  15. Carlson NG, Rojas MA, Black JD, Redd JW, Hille J, Hill KE, Rose JW. Microglial inhibition of neuroprotection by antagonists of the EP1 prostaglandin E2 receptor. J Neuroinflammation. 2009;6:5.  https://doi.org/10.1186/1742-2094-6-5
  16. Bilak M, Wu L, Wang Q, Haughey N, Conant K, St Hillaire C, Andreasson K. PGE2 receptors rescue motor neurons in a model of amyotrophic lateral sclerosis. Ann Neurol. 2004;56(2):240-248.  https://doi.org/10.1002/ana.20179
  17. Zeevalk GD, Nicklas WJ. Chemically induced hypoglycemia and anoxia: relationship to glutamate receptor-mediated toxicity in retina. J Pharmacol Exp Ther. 1990;253(3):1285-1292.
  18. Roman R, Bartkowski H, Simon R. The specific NMDA receptor antagonist AP-7 attenuates focal ischemic brain injury. Neurosci Lett. 1989;104(1-2): 19-24.  https://doi.org/10.1016/0304-3940(89)90322-4
  19. Iversen LL. Pharmacological approaches to the treatment of ischaemic neuronal damage. Eye (Lond). 1991;5(Pt 2):193-197.  https://doi.org/10.1038/eye.1991.34
  20. Benzi G, Arrigoni E, Pastoris O, Villa RF, Dagani F, Marzatico F, Agnoli A. Effect of some drugs on cerebral energy state during and after hypoxia and complete or incomplete ischemia. Biochem Pharmacol. 1979;28(3): 435-439.  https://doi.org/10.1016/0006-2952(79)90111-4
  21. Drago F, Valzelli S, Emmi I, Marino A, Scalia CC, Marino V. Latanoprost exerts neuroprotective activity in vitro and in vivo. Exp Eye Res. 2001;72(4): 479-486.  https://doi.org/10.1006/exer.2000.0975
  22. Gill R, Foster AC, Woodruff GN. Systemic administration of MK-801 protects against ischemia-induced hippocampal neurodegeneration in the gerbil. J Neurosci. 1987;7(10):3343-3349. https://doi.org/10.1523/JNEUROSCI.07-10-03343.1987
  23. Meldrum B, Garthwaite J. Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Pharmacol Sci. 1990;11(9):379-387.  https://doi.org/10.1016/0165-6147(90)90184-a
  24. Warner MA, Neill KH, Nadler JV, Crain BJ. Regionally selective effects of NMDA receptor antagonists against ischemic brain damage in the gerbil. J Cereb Blood Flow Metab. 1991;11(4):600-610.  https://doi.org/10.1038/jcbfm.1991.110
  25. Dykens JA, Stern A, Trenkner E. Mechanism of kainate toxicity to cerebellar neurons in vitro is analogous to reperfusion tissue injury. J Neurochem. 1987;49(4):1222-1228. https://doi.org/10.1111/j.1471-4159.1987.tb10014.x
  26. Goldberg MP, Weiss JH, Pham PC, Choi DW. N-methyl-D-aspartate receptors mediate hypoxic neuronal injury in cortical culture. J Pharmacol Exp Ther. 1987;243(2):784-791. 
  27. Choi DW, Koh JY, Peters S. Pharmacology of glutamate neurotoxicity in cortical cell culture: attenuation by NMDA antagonists. J Neurosci. 1988; 8(1):185-196.  https://doi.org/10.1523/JNEUROSCI.08-01-00185.1988
  28. Murphy T, Parikh A, Schnaar R, Coyle J. Arachidonic acid metabolism in glutamate neurotoxicity. In Arachidonic Acid Metabolism in the Nervous System. (Barkai AI and Bazan NG, Eds.). Ann N Y Acad Sci. 1989;559: 474-477. 
  29. Dawson VL, Dawson TM, London ED, Bredt DS, Snyder SH. Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures. Proc Natl Acad Sci USA. 1991;88(14):6368-6371. https://doi.org/10.1073/pnas.88.14.6368
  30. Pang L, Hoult JR. Induction of cyclooxygenase and nitric oxide synthase in endotoxin-activated J774 macrophages is differentially regulated by indomethacin: Enhanced cyclooxygenase-2 protein expression but reduction of inducible nitric oxide synthase. Eur J Pharmacol. 1996 Dec 12;317(1): 151-155.  https://doi.org/10.1016/S0014-2999(96)00703-0
  31. Drago F, Marino A, Floriddia ML, Marino V. Latanoprost exerts neuroprotective activity in vitro and in vivo. Invest Ophthalm Vis Sci. 1999;40;265S.
  32. Dahlmann-Noor AH, Vijay S, Limb GA, Khaw PT. Strategies for optic nerve rescue and regeneration in glaucoma and other optic neuropathies. Drug Discov Today. 2010;15(7-8):287-299.  https://doi.org/10.1016/j.drudis.2010.02.007
  33. Zheng J, Feng X, Hou L, Cui Y, Zhu L, Ma J, Xia Z, Zhou W, Chen H. Latanoprost promotes neurite outgrowth in differentiated RGC-5 cells via the PI3K-Akt-mTOR signaling pathway. Cell Mol Neurobiol. 2011;31(4): 597-604.  https://doi.org/10.1007/s10571-011-9653-x
  34. Narayanan SP, Flores AI, Wang F, Macklin WB. Akt signals through the mammalian target of rapamycin pathway to regulate CNS myelination. J Neurosci. 2009;29(21):6860-6870. https://doi.org/10.1523/JNEUROSCI.0232-09.2009
  35. Park KK, Liu K, Hu Y, Kanter JL, He Z. PTEN/mTOR and axon regeneration. Exp Neurol. 2010;223(1):45-50.  https://doi.org/10.1016/j.expneurol.2009.12.032
  36. Lingor P, Tönges L, Pieper N, Bermel C, Barski E, Planchamp V, Bähr M. ROCK inhibition and CNTF interact on intrinsic signalling pathways and differentially regulate survival and regeneration in retinal ganglion cells. Brain. 2008;131(Pt 1):250-263.  https://doi.org/10.1093/brain/awm284
  37. Vidal L, Díaz F, Villena A, Moreno M, Campos JG, Pérez de Vargas I. Reaction of Müller cells in an experimental rat model of increased intraocular pressure following timolol, latanoprost and brimonidine. Brain Res Bull. 2010;82(1-2):18-24.  https://doi.org/10.1016/j.brainresbull.2010.02.011
  38. Kudo H, Nakazawa T, Shimura M, Takahashi H, Fuse N, Kashiwagi K, Tamai M. Neuroprotective effect of latanoprost on rat retinal ganglion cells. Graefes Arch Clin Exp Ophthalmol. 2006;244(8):1003-1009. Published: 13 January 2006. https://doi.org/10.1007/s00417-005-0215-0
  39. Kanamori A, Naka M, Fukuda M, Nakamura M, Negi A. Latanoprost protects rat retinal ganglion cells from apoptosis in vitro and in vivo. Exp Eye Res. 2009;88(3):535-541.  https://doi.org/10.1016/j.exer.2008.11.012
  40. Nakanishi Y, Nakamura M, Mukuno H, Kanamori A, Seigel GM, Negi A. Latanoprost rescues retinal neuro-glial cells from apoptosis by inhibiting caspase-3, which is mediated by p44/p42 mitogen-activated protein kinase. Exp Eye Res. 2006;83(5):1108-1117. https://doi.org/10.1016/j.exer.2006.05.018
  41. Chen W, Jump DB, Grant MB, Esselman WJ, Busik JV. Dyslipidemia, but not hyperglycemia, induces inflammatory adhesion molecules in human retinal vascular endothelial cells. Invest Ophthalmol Vis Sci. 2003;44(11): 5016-5022. https://doi.org/10.1167/iovs.03-0418
  42. Joussen AM, Poulaki V, Le ML, Koizumi K, Esser C, Janicki H, Schraermeyer U, Kociok N, Fauser S, Kirchhof B, Kern TS, Adamis AP. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J. 2004;18(12):1450-1452. https://doi.org/10.1096/fj.03-1476fje
  43. Joussen AM, Poulaki V, Mitsiades N, Kirchhof B, Koizumi K, Döhmen S, Adamis AP. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASEB J. 2002;16(3):438-440. Published online January 30, 2002. https://doi.org/10.1096/fj.01-0707fje
  44. Du Y, Sarthy VP, Kern TS. Interaction between NO and COX pathways in retinal cells exposed to elevated glucose and retina of diabetic rats. Am J Physiol Regul Integr Comp Physiol. 2004;287(4):R735-R741. https://doi.org/10.1152/ajpregu.00080.2003
  45. Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, Ohyama Y, Kurabayashi M, Kaname T, Kume E, Iwasaki H, Iida A, Shiraki-Iida T, Nishikawa S, Nagai R, Nabeshima YI. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997;390(6655): 45-51.  https://doi.org/10.1038/36285
  46. Imura A, Iwano A, Tohyama O, Tsuji Y, Nozaki K, Hashimoto N, Fujimori T, Nabeshima Y. Secreted Klotho protein in sera and CSF: implication for post-translational cleavage in release of Klotho protein from cell membrane. FEBS Lett. 2004;565(1-3):143-147.  https://doi.org/10.1016/j.febslet.2004.03.090
  47. Chang Q, Hoefs S, van der Kemp AW, Topala CN, Bindels RJ, Hoenderop JG. The beta-glucuronidase Klotho hydrolyzes and activates the TRPV5 channel. Science. 2005;310(5747):490-493.  https://doi.org/10.1126/science.1114245
  48. Manya H, Inomata M, Fujimori T, Dohmae N, Sato Y, Takio K, Nabeshima Y, Endo T. Klotho protein deficiency leads to overactivation of mu-calpain. J Biol Chem. 2002;277(38):35503-35508. https://doi.org/10.1074/jbc.M206033200
  49. Ryu M, Yasuda M, Shi D, Shanab AY, Watanabe R, Himori N, Omodaka K, Yokoyama Y, Takano J, Saido T, Nakazawa T. Critical role of calpain in axonal damage-induced retinal ganglion cell death. J Neurosci Res. 2012; 90(4):802-815.  https://doi.org/10.1002/jnr.22800
  50. Liu S, Yin F, Zhang J, Qian Y. The role of calpains in traumatic brain injury. Brain Inj. 2014;28(2):133-137.  https://doi.org/10.3109/02699052.2013.860479
  51. Farinelli P, Arango-Gonzalez B, Völkl J, Alesutan I, Lang F, Zrenner E, Paquet-Durand F, Ekström PA. Retinitis Pigmentosa: over-expression of anti-ageing protein Klotho in degenerating photoreceptors. J Neurochem. 2013; 127(6):868-879.  https://doi.org/10.1111/jnc.12353
  52. Kokkinaki M, Abu-Asab M, Gunawardena N, Ahern G, Javidnia M, Young J, Golestaneh N. Klotho regulates retinal pigment epithelial functions and protects against oxidative stress. J Neurosci. 2013;33(41):16346-16359. https://doi.org/10.1523/JNEUROSCI.0402-13.2013
  53. Zeldich E, Chen C-D, Colvin TA, Bove-Fenderson EA, Liang J, Tucker Zhou TB, Harris DA, Abraham CR. The neuroprotective effect of Klotho is mediated via regulation of members of the redox system. J Biol Chem. 2014; 289(35):24700-24715. https://doi.org/10.1074/jbc.M114.567321
  54. Yamamoto K, Sato K, Yukita M, Yasuda M, Omodaka K, Ryu M, et al. The neuroprotective effect of latanoprost acts via klotho-mediated suppression of calpain activation after optic nerve transection. J Neurochem. 2016; 140(3): 495-508.  https://doi.org/10.1111/jnc.13902
  55. Stalmans I, Oddone F, Cordeiro MF, Hommer A, Montesano G, Ribeiro L, et al. Comparison of preservative-free latanoprost and preservative-free bimatoprost in a multicenter, randomized, investigator-masked cross-over clinical trial, the SPORT trial. Graefe’s Arch Clin Exp Ophthalmol. 2016; 254(6):1151-1158. https://doi.org/10.1007/s00417-016-3299-9
  56. Kurysheva NI, Azizova OA, Piryazev AP. A Comparative Study into Antioxidant Activity of Fixed Combinations in Topical Glaucoma Treatment. Rossiiskij oftal’mologicheskij zhurnal. 2013;2(6):41-44. (In Russ.).
  57. Fuma S, Shimazawa M, Imamura T, Kanno Y, Takano N, Tsuruma K, et al. Neuroprotective Effect of Ocular Hypotensive Drugs: Latanoprost/Timolol in Combination Are More Effective than Each as Monotherapy in RGC5. Biol Pharm Bull. 2016;39(2):192-198.  https://doi.org/10.1248/bpb.b15-00584
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.